Organization (Other)
Debiopharm International SA
ClinicalTrials.gov lists Debiopharm International SA as lead sponsor of 51 trials. It has 39 active development programs and 24 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Debiopharm International SA: 51 lead-sponsored trials and 2 legal-entity registrations. The parent company on record for Debiopharm International SA is Après-demain SA, which does not have its own page on this site.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (39)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Hepatitis C | 10 |
| Hepatitis C, Chronic | 7 |
| Lymphoma | 5 |
| Prostatic Neoplasms | 4 |
| Lung Neoplasms | 3 |
Showing 5 of 39 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 5 |
| 2019 | 5 |
| 2017 | 3 |
| 2016 | 2 |
| 2015 | 2 |
Showing 10 of 18 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 42 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (39)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Debio 4126 | Acromegaly | Phase 3 | 2 |
| Debio 4326 | Puberty, Precocious | Phase 3 | 1 |
| Debio 4126 | Gigantism | Phase 3 | 1 |
| Debio 4228 | Prostatic Neoplasms | Phase 2 | 1 |
| RITUXIMAB | Lymphoma | Phase 2 | 1 |
Showing 5 of 39 active programs.
Approved assets (24)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ribavirin | 9 |
| PEGinterferon alfa-2a | 5 |
| Triptorelin Pamoate | 1 |
| Boceprevir | 1 |
| Triptorelin | 1 |
Showing 5 of 24 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 29% hit target (n=14) | 7% on time (n=14) |
Journals published in (47)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 7 |
| Hepatology (Baltimore, Md.) | 6 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 5 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 3 |
| Gastroenterology | 3 |
Showing 5 of 47 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 20 | 9 | 2025-11-18 |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 1 |
| Syneos Health (United States) | Uses vendor | 1 |
| Parexel | Uses vendor | 1 |
Latest dated events (82)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-26 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 82 events.
Biomarker capability evidence (138)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| CCND1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 138 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.